Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Investing Activities (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Cash from Investing Activities data on record, last reported at -$513000.0 in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 191.48% year-over-year to -$513000.0; the TTM value through Sep 2025 reached -$988000.0, up 27.03%, while the annual FY2024 figure was -$1.0 million, 70.5% up from the prior year.
  • Cash from Investing Activities reached -$513000.0 in Q3 2025 per NWBO's latest filing, down from -$304000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$58000.0 in Q1 2022 and bottomed at -$2.7 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$751473.7, with a median of -$418000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: soared 89.74% in 2022, then tumbled 2198.28% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$1.6 million in 2021, then crashed by 39.09% to -$2.2 million in 2022, then skyrocketed by 80.65% to -$418000.0 in 2023, then soared by 81.34% to -$78000.0 in 2024, then crashed by 557.69% to -$513000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$513000.0 in Q3 2025, -$304000.0 in Q2 2025, and -$93000.0 in Q1 2025.